Alomide
FDA Approves Retinal Implant for Rare Genetic Eye Disease »
"The U.S. Food and Drug Administration today approved the Argus II Retinal Prosthesis System, the first implanted device to treat adult patients with advanced retinitis pigmentosa (RP). The device, which includes a small video camera, transmitter "...
Read the FDA Approves Retinal Implant for Rare Genetic Eye Disease article »
Alomide
INDICATIONS
ALOMIDE® (lodoxamide tromethamine ophthalmic solution) 0.1% is indicated in the treatment of the ocular disorders referred to by the terms vernal keratoconjunctivitis, vernal conjunctivitis, and vernal keratitis.
DOSAGE AND ADMINISTRATION
The dose for adults and children greater than two years of age is one to two drops in each affected eye four times daily for up to 3 months.
HOW SUPPLIED
ALOMIDE® (lodoxamide tromethamine ophthalmic solution) 0.1% is supplied in plastic ophthalmic DROP-TAINER® dispenser as follows:
10 mL: NDC 0065-0345-10
Storage
Store at 15°C - 27°C (59°F - 80°F).
ALCON LABORATORIES, INC., Fort Worth, Texas 76134 USA. FDA revision date: 06/26/03
Last reviewed on RxList: 8/14/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Alomide Information
Alomide - User Reviews
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
WebMD Daily
Get breaking medical news.






